Advanced

 
  Search
    Simple search


Results

5 results
1 - 5 / 5
First pagePrevious page1Next pageLast page
1. Primerjava bolnikov v redni klinični praksi in tistih, vključenih v randomizirana klinična preskušanja tarčnih zdravil za Crohnovo bolezen: pomen vključitvenih in izključitvenih kriterijev
Tina Kodrič, 2024, master's thesis/paper

Keywords: Crohnova bolezen, biološka zdravila, majhne molekule, kronična vnetna črevesna bolezen, retrospektivna raziskava
Full text (file, 1,46 MB)

2. Povezava serumskih koncentracij vedolizumaba in ustekinumaba z izidi zdravljenja pri kronični vnetni črevesni bolezni
Jurij Hanžel, 2022, doctoral dissertation

Keywords: kronična vnetna črevesna bolezen, vedolizumab, ustekinumab, farmakokinetika, terapevtsko spremljanje serumskih koncentracij
Full text (file, 2,49 MB)

3. Ustekinumab dosing individualization in Crohn's disease guided by a population pharmacokinetic-pharmacodynamic model
Jurij Zdovc, Jurij Hanžel, Borut Štabuc, Tomaž Vovk, Barbara Ostanek, David Drobne, Iztok Grabnar, 2021, original scientific article

Keywords: ustekinumab, inflammatory bowel disease, fecal calprotectin, pharmacokinetics-pharmacodynamics, therapeutic drug monitoring
Full text (file, 1,20 MB) This document has more files! More...

4. Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with Crohn disease
Jurij Hanžel, Erwin Dressen, Séverine Vermeire, Mark Löwenberg, Frank Hoentjen, Peter Bossuyt, Esmé Clasquin, Filip J. Baert, Geert R. D'Haens, Ron Mathôt, 2022, original scientific article

Keywords: therapeutic drug monitoring, exposure-response, pharmacometrics, inflammatory bowel disease, Crohn's disease, drug clearance, endoscopy, pharmacodynamics, infusion procedures, disease remission, vedolizumab, therapy
Full text (file, 2,05 MB) This document has more files! More...

5. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease
Jurij Hanžel, Jeroen M. Jansen, Rinze W. F. ter Steege, Krisztina B. Gecse, Geert R. D'Haens, 2022, original scientific article

Keywords: SB2, CT-P13, multiple switches, Crohn's disease, inflammatory bowel disease, ulcerative colitis, adults, feces, c-reactive protein, infliximab, adverse event, leukocyte l1 antigen complex, infusion procedures, biosimilar pharmaceuticals, disease remission, imputation, antidrug antibody, infliximab-dyyb
Full text (file, 608,73 KB) This document has more files! More...
Search done in 0.02 sec.
Back to top